[Vaccination against herpes-zoster: a new strategy for post-herpetic neuralgia].
Herpes zoster results from reactivation of latent varicella-zoster virus within the sensory ganglia after primary infection. Its presence in adult age is commonly complicated with post-herpetic neuralgia. Annual hospitalization rate is about 21 cases per 100,000 person older than 50 years. Herpes zoster is an important contributor to morbidity in adults, increased in immunocompromised patients. Recent approval of a safe and effective herpes-zoster vaccine allows the optimization of population immunization strategies and the improvement of the impact of vaccination in herpes-zoster and varicella epidemiology.
Gil de Miguel
Angel
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D006562:Herpes Zoster / Q000453:epidemiology / Q000517:prevention & control*; D053061:Herpes Zoster Vaccine; D006801:Humans; D007223:Infant; D008875:Middle Aged; D051474:Neuralgia, Postherpetic / Q000517:prevention & control*; D013030:Spain; D055815:Young Adult
D053061:Herpes Zoster Vaccine